Body Vision Medical Signs Exclusive Distribution Agreement with AMCO Incorporated
June 04 2024 - 11:46AM
Business Wire
Distribution Agreement Brings LungVision® AI-Powered Image
Guidance to Japan
Body Vision Medical, a leader in AI-driven, intraoperative
imaging, announced today it has signed an exclusive distribution
agreement with AMCO Incorporated to expand access of its
cutting-edge LungVision® real-time, intraoperative CT imaging
system to Japan.
LungVision® uses artificial intelligence (AI) to transform any
C-arm fluoroscope into an intraoperative tomographic imaging system
with advanced navigation capabilities. LungVision’s real-time
imaging gives bronchoscopists the confidence to biopsy from small
pulmonary lesions with greater speed and precision, maximizing the
likelihood for earlier-stage cancer detection and improved lung
cancer survival.
“Japan has the highest lung cancer screening adoption rate of
any country in the world,” said Jon Ulvestad, VP of Sales and
Market Development at Body Vision Medical. “This translates into a
need to definitively diagnose a large number of patients identified
with suspicious pulmonary nodules. LungVision® provides the
Japanese healthcare system a clinically- and cost-effective means
to diagnose lung cancer patients at scale and this agreement with
AMCO is a key milestone in giving Japanese clinicians and patients
access to the latest in lung cancer diagnostics technology.”
About AMCO Incorporated
For over seventy years, AMCO Incorporated, with head office in
Tokyo, Japan, has been involved in successfully importing,
marketing, and servicing medical and scientific products from the
USA and Europe. We have worked hard to maintain a leadership
position in the Japanese market by introducing state-of-the-art
technology and products. We are proud of our long history of
success in Japan and continue to actively seek new and innovative
medical and scientific products from around the world.
Visit https://amco.co.jp/ to learn more.
About Body Vision Medical
Body Vision Medical believes in saving lives through the
democratization of innovative medical technology and the Quintuple
Aim is at the heart of everything that we do. Our first commercial
product, LungVision®, provides AI-powered real-time image guidance
to address the unmet clinical need for early, definitive lung
cancer diagnosis and, in the future, to enable effective treatment
of lung lesions via a minimally invasive procedure.
Visit bodyvisionmedical.com to learn more and connect with us on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240604334123/en/
Victor Chan +1.415.794.1053 info@bodyvisionemedical.com